MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2025016651

Медицинская библиотека · Blood advances · 2025

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Collinge Brett, Hilton Laura K, Wong Jasper, Alduaij Waleed, Ben-Neriah Susana, Slack Graham W, Farinha Pedro, Boyle Merrill, Meissner Barbara, Cook James R, Ott German, Rosenwald Andreas, Campo Elias, Amador Catalina, Greiner Timothy C, Raess Philipp W, Song Joo Y, Inghirami Giorgio, Ondrejka Sarah L, Jaffe Elaine S, Weisenburger Dennis D, Chan Wing C, Holte Harald, Beiske Klaus, Fu Kai, Delabie Jan, Pittaluga Stefania, Iqbal Javeed, Wright George, Savage Kerry J, Mungall Andrew J, Staudt Louis M, Steidl Christian, Feldman Andrew L, Morin Ryan D, Rimsza Lisa M, Scott David W

СтатьяПеревод в очереди

Аннотация

Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell-like (GCB), and 25% were activated B-cell-like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig- GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.

Для цитирования: Collinge Brett, Hilton Laura K, Wong Jasper, Alduaij Waleed, Ben-Neriah Susana, Slack Graham W, Farinha Pedro, Boyle Merrill, Meissner Barbara, Cook James R, Ott German, Rosenwald Andreas, Campo Elias, Amador Catalina, Greiner Timothy C, Raess Philipp W, Song Joo Y, Inghirami Giorgio, Ondrejka Sarah L, Jaffe Elaine S, Weisenburger Dennis D, Chan Wing C, Holte Harald, Beiske Klaus, Fu Kai, Delabie Jan, Pittaluga Stefania, Iqbal Javeed, Wright George, Savage Kerry J, Mungall Andrew J, Staudt Louis M, Steidl Christian, Feldman Andrew L, Morin Ryan D, Rimsza Lisa M, Scott David W. High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.. Blood advances. 2025. DOI: 10.1182/bloodadvances.2025016651.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.